http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Soft X-ray magnetic circular dichroism of Cr-doped GaN
H.Makino,J.J.Kim,T.Nakamura,T.Muro,K.Kobayashi,T.Yao 한국물리학회 2004 Current Applied Physics Vol.4 No.6
Soft X-ray magnetic circular dichroism (XMCD) have been measured for the Ga0:97Cr0:03N lm grown by NH3-assistedmolecular beam epitaxy. Temperature dependence of the XMCD intensity was well described by the CurieWeiss law. Although thesample showed ferromagnetic behavior at least up to room temperature, the ferromagnetic component could not be detected by the XMCD measurement.
Non-invasive Assessment of Neuromuscular and Cardiovacular Fitness
Chung,So-Young,Kim,Yong-Jin,Muro, Moritani T. 忠南大學校體育科學硏究所 1996 體育科學硏究誌 Vol.14 No.1
본 논문에서는 무산소성역치(anaerobic threshold, AT)와 신경근의 피로역치에서 최대파워산출(EMGFT)을 결정하는 심전도기술(EMG technique)에 대해 자세히 기술하고자 한다. 또한 인체 근섬유 유형의 조성을 결정하는 비침해성(non-invasive)방법에 대해 보고하고자 한다. 이 방법은 1)심전도 주파수 파워의 분광학적 변수인 평균 파워 주파수(mean power frequency, MPF)와 근평균 제곱근 크기(root meqan square amplitude, RMS), 2)최대 연축 수축 지표(dF/dtmax, electromechanical delay time, EMD), 3)지속된 50% 최대임의 근수축시 근피로도에 근거하여 결정하였다. 마지막으로 심혈관 신경의 통합성과 적합성을 검정하기 위해서 최신의 ECR-RR interval 파워의 분광학적 분석에 대해 자세히 논의하고자 한다.
Al-Batran, S.-E.,Van Cutsem, E.,Oh, S. C.,Bodoky, G.,Shimada, Y.,Hironaka, S.,Sugimoto, N.,Lipatov, O. N.,Kim, T.-Y.,Cunningham, D.,Rougier, P.,Muro, K.,Liepa, A. M.,Chandrawansa, K.,Emig, M.,Ohtsu, A Oxford University Press 2016 Annals of Oncology Vol.27 No.4
<P><B>Background</B></P><P>The phase III RAINBOW trial demonstrated that the addition of ramucirumab to paclitaxel improved overall survival, progression-free survival, and tumor response rate in fluoropyrimidine–platinum previously treated patients with advanced gastric/gastroesophageal junction (GEJ) adenocarcinoma. Here, we present results from quality-of-life (QoL) and performance status (PS) analyses.</P><P><B>Patients and methods</B></P><P>Patients with Eastern Cooperative Oncology Group PS of 0/1 were randomized to receive ramucirumab (8 mg/kg i.v.) or placebo on days 1 and 15 of a 4-week cycle, with both arms receiving paclitaxel (80 mg/m<SUP>2</SUP>) on days 1, 8, and 15. Patient-reported outcomes were assessed with the QoL/health status questionnaires EORTC QLQ-C30 and EQ-5D at baseline and 6-week intervals. PS was assessed at baseline and day 1 of every cycle. Time to deterioration (TtD) in each QLQ-C30 scale was defined as randomization to first worsening of ≥10 points (on 100-point scale) and TtD in PS was defined as first worsening to ≥2. Hazard ratios (HRs) for treatment effect were estimated using stratified Cox proportional hazards models.</P><P><B>Results</B></P><P>Of the 665 patients randomized, 650 (98%) provided baseline QLQ-C30 and EQ-5D data, and 560 (84%) also provided data from ≥1 postbaseline time point. Baseline scores for both instruments were similar between arms. Of the 15 QLQ-C30 scales, 14 had HR < 1, indicating similar or longer TtD in QoL for ramucirumab + paclitaxel. Treatment with ramucirumab + paclitaxel was also associated with a delay in TtD in PS to ≥2 (HR = 0.798, <I>P</I> = 0.0941). Alternate definitions of PS deterioration yielded similar results: PS ≥ 3 (HR = 0.656, <I>P</I> = 0.0508), deterioration by ≥1 PS level (HR = 0.802, <I>P</I> = 0.0444), and deterioration by ≥2 PS levels (HR = 0.608, <I>P</I> = 0.0063). EQ-5D scores were comparable between treatment arms, stable during treatment, and worsened at discontinuation.</P><P><B>Conclusion</B></P><P>In patients with previously treated advanced gastric/GEJ adenocarcinoma, addition of ramucirumab to paclitaxel prolonged overall survival while maintaining patient QoL with delayed symptom worsening and functional status deterioration.</P><P><B>ClinicalTrials.gov</B></P><P>NCT01170663.</P>